Patents by Inventor Todd C. Somers

Todd C. Somers has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Low molecular weight peptidomimetic growth hormone secretagogues
    Patent number: 7094869
    Abstract: The present invention comprises growth hormone releasing peptides/peptidomimetics (GHRP) capable of causing release of growth hormone from the pituitary. Compositions containing the GHRP's of this invention are used to promote growth in mammals either alone or in combination with other growth promoting compounds, especially IGF-1. In a method of this invention GHRP's in combination with IGF-1 are used to treat Type II diabetes.
    Type: Grant
    Filed: August 19, 2002
    Date of Patent: August 22, 2006
    Assignee: Genentech, Inc.
    Inventors: Todd C. Somers, Kathleen A. Elias, Ross G. Clark, Robert S. McDowell, Mark S. Stanley, John P. Burnier, Thomas E. Rawson
  • Low molecular weight peptidomimetic growth hormone secretagogues
    Publication number: 20030139348
    Abstract: The present invention comprises growth hormone releasing peptides/peptidomimetics (GHRP) capable of causing release of growth hormone from the pituitary. Compositions containing the GHRP's of this invention are used to promote growth in mammals either alone or in combination with other growth promoting compounds, especially IGF-1. In a method of this invention GHRP's in combination with IGF-1 are used to treat Type II diabetes. An exemplary compound of this invention is provided below.
    Type: Application
    Filed: August 19, 2002
    Publication date: July 24, 2003
    Applicant: Genentech, Inc.
    Inventors: Todd C. Somers, Kathleen A. Elias, Ross G. Clark, Robert S. McDowell, Mark S. Stanley, John P. Burnier, Thomas E. Rawson
  • LOW MOLECULAR WEIGHT PEPTIDOMIMETIC GROWTH HORMONE SECRETAGOGUES
    Publication number: 20020111461
    Abstract: The present invention comprises growth hormone releasing peptides/peptidomimetics (GHRP) capable of causing release of growth hormone from the pituitary. Compositions containing the GHRP's of this invention are used to promote growth in mammals either alone or in combination with other growth promoting compounds, especially IGF-1. In a method of this invention GHRP's in combination with IGF-1 are used to treat Type II diabetes. An exemplary compound of this invention is provided below.
    Type: Application
    Filed: May 21, 1999
    Publication date: August 15, 2002
    Inventors: TODD C. SOMERS, KATHLEEN A. ELIAS, ROSS G. CLARK, ROBERT S. MCDOWELL, MARK S. STANLEY, JOHN P. BURNIER, THOMAS E. RAWSON
  • Benzodiazepine derivatives for imaging thrombi
    Patent number: 6171578
    Abstract: The invention provides compounds comprising glycoprotein IIb/IIIa receptor-binding benzodiazepine derivatives covalently linked to metal ion chelators. The compounds of the invention may be labeled with a radionuclide such as 99mTc and used to image thrombi.
    Type: Grant
    Filed: April 14, 1999
    Date of Patent: January 9, 2001
    Assignees: Diatide, Inc., Genentech, Inc.
    Inventors: Richard T. Dean, John Lister-James, Michael C. Venuti, Todd C. Somers
  • Low molecular weight peptidomimetic growth hormone secretagogues
    Patent number: 6034216
    Abstract: The present invention comprises growth hormone releasing peptides/peptidomimetics (GHRP) capable of causing release of growth hormone from the pituitary. Compositions containing the GHRP's of this invention are used to promote growth in mammals either alone or in combination with other growth promoting compounds, especially IGF-1. In a method of this invention GHRP's in combination with IGF-1 are used to treat Type II diabetes. An exemplary compound of this invention is provided below.
    Type: Grant
    Filed: April 8, 1998
    Date of Patent: March 7, 2000
    Assignee: Genentech Inc.
    Inventors: Todd C. Somers, Kathleen A. Elias, Ross G. Clark, Robert S. McDowell, Mark S. Stanley, John P. Burnier, Thomas E. Rawson
  • Ras farnesyl transferase inhibitors
    Patent number: 5843941
    Abstract: Benzodiazepine derivatives represented by the structure below are disclosed that act as potent inhibitors of ras farnesyl:protein transferase. Pharmaceutical compositions containing these benzodiazepines are provided for treatment of diseases foe which inhibition of the ras farnesyl:protein transferase as indicated.
    Type: Grant
    Filed: September 26, 1994
    Date of Patent: December 1, 1998
    Assignees: Genentech, Inc., Board of Regents University of Texas
    Inventors: James C. Marsters, Jr., Michael S. Brown, Craig W. Crowley, Joseph L. Goldstein, Guy L. James, Robert S. McDowell, David Oare, Thomas E. Rawson, Mark Reynolds, Todd C. Somers
  • Low molecular weight peptidomimetic growth hormone secretagogues
    Patent number: 5798337
    Abstract: The present invention comprises growth hormone releasing peptides/peptidomimetics (GHRP) capable of causing release of growth hormone from the pituitary. Compositions containing the GHRP's of this invention are used to promote growth in mammals either alone or in combination with other growth promoting compounds, especially IGF-1. In a method of this invention GHRP's in combination with IGF-1 are used to treat Type II diabetes. An exemplary compound of this invention is provided below.
    Type: Grant
    Filed: November 16, 1994
    Date of Patent: August 25, 1998
    Assignee: Genentech, Inc.
    Inventors: Todd C. Somers, Kathleen A. Elias, Ross G. Clark, Robert S. McDowell, Mark S. Stanley, John P. Burnier, Thomas E. Rawson
  • Tricyclic inhibitors of the vitronectin receptor
    Patent number: 5716951
    Abstract: A tricylic benzodiazepine derivative that acts as a nonpeptidyl platelet aggregation inhibitor is provided. This inhibitor potently inhibits fibrinogen binding to the GPII.sub.b III.sub.a receptor and is provided in therapeutic compositions for the treatment of diseases for which blocking platelet aggregation is indicated. These nonpeptidyl inhibitors are provided in combination with thrombolytics and anticoagulants.
    Type: Grant
    Filed: May 8, 1995
    Date of Patent: February 10, 1998
    Assignee: Genentech, Inc.
    Inventors: Brent K. Blackburn, Kirk Robarge, Todd C. Somers
  • Tricyclic inhibitors of the GPII.sub.b III.sub.a receptor
    Patent number: 5705890
    Abstract: A tricylic benzodiazepine derivative that acts as a nonpeptidyl platelet aggregation inhibitor is provided. This inhibitor potently inhibits fibrinogen binding to the GPII.sub.b III.sub.a receptor and is provided in therapeutic compositions for the treatment of diseases for which blocking platelet aggregation is indicated. These nonpeptidyl inhibitors are provided in combination with thrombolytics and anticoagulants.
    Type: Grant
    Filed: September 26, 1994
    Date of Patent: January 6, 1998
    Assignee: Genentech, Inc.
    Inventors: Brent K. Blackburn, Kirk Robarge, Todd C. Somers
  • Ras farnesyl transferase inhibitors
    Patent number: 5532359
    Abstract: Benzodiazepine derivatives are disclosed that act as potent inhibitors of ras farnesyl:protein transferase. Pharmaceutical compositions containing these benzodiazepines are provided for treatment of diseases for which inhibition of the ras farnesyl:protein transferase is indicated.
    Type: Grant
    Filed: October 25, 1994
    Date of Patent: July 2, 1996
    Assignees: Genentech, Inc., Board of Regents, The University of Texas System
    Inventors: James C. Marsters, Jr., Michael S. Brown, Craig W. Crowley, Joseph L. Goldstein, Guy L. James, Robert S. McDowell, David Oare, Thomas E. Rawson, Mark Reynolds, Todd C. Somers
  • Tricyclic inhibitors of the GPII.sub.b III.sub.a receptor
    Patent number: 5493020
    Abstract: A trycylic benzodiazepine derivative which acts as a nonpeptidyl platelet aggregation inhibitor is provided. This inhibitor potently inhibits fibrinogen binding to the GPII.sub.b III.sub.a receptor and is provided in therapeutic compositions for the treatment of diseases for which blocking platelet aggregation is indicated. These nonpeptidyl inhibitors are provided in combination with thrombolytics and anticoagulants.
    Type: Grant
    Filed: July 29, 1993
    Date of Patent: February 20, 1996
    Assignee: Genentech, Inc.
    Inventors: Brent K. Blackburn, Kirk Robarge, Todd C. Somers
  • Ketamine analogues for treatment of thrombocytopenia
    Patent number: 5384331
    Abstract: 5,6-Dehydronorketamine and derivatives retaining the .alpha.,.beta.-unsaturated carbonyl are disclosed. These end other Michael or Michael-type acceptors and adducts are shown to influence the replication, differentiation or maturation of blood cells, especially platelet progenitor cells. Accordingly, these compounds are used for treatment of thrombocytopenia.
    Type: Grant
    Filed: May 28, 1993
    Date of Patent: January 24, 1995
    Assignee: Genentech, Inc.
    Inventors: Timothy P. Kogan, Todd C. Somers
  • Ketamine analogues for treatment of thrombocytopenia
    Patent number: 5250732
    Abstract: 5,6-Dehydronorketamine and derivatives retaining the .alpha.,.beta.-unsaturated carbonyl are disclosed. These and other Michael or Michael-type acceptors and adducts are shown to influence the replication, differentiation or maturation of blood cells, especially platelet progenitor cells. Accordingly, these compounds are used for treatment of thrombocytopenia.
    Type: Grant
    Filed: July 18, 1991
    Date of Patent: October 5, 1993
    Assignee: Genentech, Inc.
    Inventors: Timothy P. Kogan, Todd C. Somers